trial with title TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US

*NOTE - some study locations are open, while others remain temporarily closed due to the impact of Coronavirus (COVID-19)*

Find a participating research site

If you are interested in taking part in this study, begin typing your location below and then select from the dropdown list. The map will update with sites within the distance you select with a list of locations below.

Please note the map below only lists study sites that are accepting online referrals. If you cannot find a site in your area please check back again as study sites can be added to the study on an ongoing basis.

Alternatively, if you wish to see the full listing of all study sites visit clinicaltrials.gov.

Select Country

Site Name Address Status Distance
Banner MD Anderson Cancer Center
2940 East Banner Gateway Drive
Gilbert, AZ, 85234
United States
Recruiting -- Am I Eligible?
Barbara Ann Karmanos Cancer Institute
4100 John R Street
Detroit, Mi, 48201
United States
Recruiting -- Am I Eligible?
Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, MA, 02215
United States
Recruiting -- Am I Eligible?
City of Hope Comprehensive Cancer Center - Duarte
1500 East Duarte Road
Duarte, CA, 91010
United States
Recruiting -- Am I Eligible?
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue
Seattle, WA, 98109
United States
Recruiting -- Am I Eligible?
Georgetown University Medical Center
3800 Reservoir Road Northwest
Washington, DC, 20007
United States
Recruiting -- Am I Eligible?
Hackensack University Medical Center
92 2nd Street
Hackensack, NJ, 07601
United States
Recruiting -- Am I Eligible?
Huntsman Cancer Institute
2000 Circle of Hope Drive
Salt Lake City, UT, 84112
United States
Recruiting -- Am I Eligible?
Peggy and Charles Stephenson Oklahoma Cancer Center
800 Northeast 10th Street
Oklahoma City, OK, 73104
United States
Recruiting -- Am I Eligible?
The Blood and Marrow Transplant Group of Georgia
5670 Peachtree Dunwoody Road
Atlanta, GA, 30342
United States
Recruiting -- Am I Eligible?
Thomas Jefferson University
1015 Chestnut Street
Philadelphia, PA, 19107
United States
Recruiting -- Am I Eligible?
University Hospitals Seidman Cancer Center
11100 Euclid Avenue
Cleveland, OH, 44106
United States
Recruiting -- Am I Eligible?
University of Nebraska Medical Center
986846 Nebraska Medical Center
Omaha, NE, 68198
United States
Recruiting -- Am I Eligible?
University of Pennsylvania
3400 Civic Center Boulevard
Philadelphia, Pa, 19104
United States
Recruiting -- Am I Eligible?
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd
Dallas, TX, 75390
United States
Recruiting -- Am I Eligible?
Virginia Commonwealth University
1300 E Marshall Street
Richmond, VA, 23298
United States
Recruiting -- Am I Eligible?
Weill Cornell Medical College
520 East 70th Street
New York, NY, 10065
United States
Recruiting -- Am I Eligible?

For more information, please watch the video.

Participation in the study lasts approximately 26 months. This includes:

  • A pretreatment period that will occur seven days before the treatment period. During this time, the study doctor will confirm if you are eligible for treatment. If you are eligible, baseline measurements will be taken.
  • A treatment period that will last up to 30 days. The treatment is a one-day infusion, with a concentrated follow-up period in the first 30 days.
  • A follow-up period when you will visit the study site at least eight times before your participation in the study ends. This period will last two years.

The investigational study drug used in TRANSCEND CLL 004 is called JCAR017. This drug is the result of a modification to a participant’s own immune cells (T cells) with a chimeric antigen receptor (CAR). These modified T cells (CAR T cells), may target and reduce the number of cancer cells, which then could provide an environment for healthy cells to grow normally.  JCAR017 is administered once as an infusion during the treatment period.